Muscle Relaxant Guidelines

Introduction to Muscle Relaxants

The American Geriatrics Society and the American Academy of Neurology recommend starting muscle relaxants such as tizanidine at a lower dose (2 mg up to three times daily) and monitoring for muscle weakness, urinary function changes, cognitive effects, sedation, and orthostatic hypotension, with a moderate strength of evidence for its benefits in perioperative pain control, reduced midazolam requirements, decreased opioid consumption, and hemodynamic stability 1, 2

Tizanidine has potential for many drug-drug interactions, and its use is contraindicated with CYP1A2 inhibitors, and methocarbamol interferes with the effects of pyridostigmine bromide and should not be used in patients with myasthenia gravis, as noted by the American Geriatrics Society and the Mayo Clinic Proceedings 1, 2

Patients with liver or kidney disease require careful monitoring and potential dose adjustments, and elderly patients should start at lower doses due to increased risk of sedative and hypotensive effects, with significant dose reductions required in patients with hepatic or renal impairment, as recommended by the American Academy of Neurology and other guideline societies 1, 2
Methocarbamol dosing should account for potential sedative effects and be held on the day of surgical procedures, with significant dose reductions required in patients with liver and kidney disease, as recommended by the Mayo Clinic Proceedings 2

Tizanidine dosing should start at a lower dose and titrate gradually, with a maximum daily dose of 36 mg, and food significantly affects tizanidine pharmacokinetics, requiring consistent administration to avoid fluctuations in drug levels, as stated by the Mayo Clinic Proceedings 2

Tizanidine is an α2-adrenergic receptor agonist with common adverse effects including dose-dependent sedation, drowsiness, dizziness, ataxia, and lethargy, and patients who experience hallucinations while taking tizanidine should discontinue the medication immediately and contact their healthcare provider, as this is a documented adverse effect that requires prompt medical attention, with a moderate strength of evidence supporting slow tapering when stopping tizanidine, especially after long-term use, to avoid withdrawal symptoms 2, 3

Alternative muscle relaxants such as cyclobenzaprine, baclofen, methocarbamol, and metaxalone may be considered, though each has its own potential side effects and considerations, including anticholinergic effects, withdrawal symptoms, and different side effect profiles, as noted by the Mayo Clinic Proceedings 2

Patients should always inform healthcare providers about their history of hallucinations with tizanidine, be particularly cautious with other α2-adrenergic agonists or centrally acting muscle relaxants, start any new muscle relaxant at the lowest possible dose with gradual titration, and report any unusual symptoms promptly to their healthcare provider, as recommended by the Mayo Clinic Proceedings 2